Literature DB >> 15649564

Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus.

Nonia Pariente1, Saleta Sierra, Antero Airaksinen.   

Abstract

Our current knowledge on foot-and-mouth disease virus (FMDV) entry into error catastrophe is reviewed. FMDV can establish cytolytic and persistent infections in the field and in cell culture. Both types of FMDV infection in cell culture can be treated with mutagens, with or without classical (non-mutagenic) antiviral inhibitors, to drive the virus to extinction. 5-Fluorouracil (FU) and 5-azacytidine (AZC) have been employed as mutagenic agents to treat cytolytic FMDV infections, and ribavirin (Rib) to treat persistent infections. Extinction is dependent on the relative fitness of the viral isolate, as well as on the viral load. In cytolytic infections, extinctions could be efficiently obtained with combinations of mutagens and inhibitors. High-fitness FMDV extinction could only be achieved with treatments that contained a mutagen, and not with combinations of inhibitors that exerted the same antiviral effect. Persistent infections could be cured with Rib treatment alone. The results presented here show entry into error catastrophe as a valid strategy for treatment of viral infections, although much work remains to be done before it can be implemented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649564     DOI: 10.1016/j.virusres.2004.11.008

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  18 in total

Review 1.  Examining the theory of error catastrophe.

Authors:  Jesse Summers; Samuel Litwin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Authors:  Ana Grande-Pérez; Gema Gómez-Mariano; Pedro R Lowenstein; Esteban Domingo
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence.

Authors:  Jianxiong Zeng; Haiwei Wang; Xiaochun Xie; Chen Li; Guohui Zhou; Decheng Yang; Li Yu
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

4.  Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach.

Authors:  Jaime Iranzo; Celia Perales; Esteban Domingo; Susanna C Manrubia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-12       Impact factor: 11.205

5.  Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe.

Authors:  Macarena Sierra; Antero Airaksinen; Claudia González-López; Rubén Agudo; Armando Arias; Esteban Domingo
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

6.  Genetic and phenotypic variation of foot-and-mouth disease virus during serial passages in a natural host.

Authors:  C Carrillo; Z Lu; M V Borca; A Vagnozzi; G F Kutish; D L Rock
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

7.  Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.

Authors:  Ryan C Durk; Kamalendra Singh; Ceili A Cornelison; Devendra K Rai; Kayla B Matzek; Maxwell D Leslie; Elizabeth Schafer; Bruno Marchand; Adeyemi Adedeji; Eleftherios Michailidis; Christopher A Dorst; Jennifer Moran; Christie Pautler; Luis L Rodriguez; Mark A McIntosh; Elizabeth Rieder; Stefan G Sarafianos
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240

Review 8.  Quasispecies theory and the behavior of RNA viruses.

Authors:  Adam S Lauring; Raul Andino
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

9.  Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection.

Authors:  Héctor Moreno; Héctor Tejero; Juan Carlos de la Torre; Esteban Domingo; Verónica Martín
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

10.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.